The Resource Screening for bilirubin encephalopathy, investigators, Stanley Ip ... [et al.], (electronic resource)

Screening for bilirubin encephalopathy, investigators, Stanley Ip ... [et al.], (electronic resource)

Label
Screening for bilirubin encephalopathy
Title
Screening for bilirubin encephalopathy
Statement of responsibility
investigators, Stanley Ip ... [et al.]
Contributor
Subject
Language
  • eng
  • eng
Summary
BACKGROUND: Kernicterus or chronic bilirubin encephalopathy is a devastating disease. Thus, it is important to examine strategies to prevent the development of kernicterus. PURPOSE: To systematically review evidence for the effectiveness of strategies to prevent chronic bilirubin encephalopathy. This is an update of our previous evidence report. DATA SOURCES: We searched Medline for articles from September, 2001 to August, 2007 using the MeSH terms and keywords, such as "jaundice," "bilirubin," "hyperbilirubinemia," and "kernicterus." For additional studies, we examined the bibliographies in existing studies and also consulted the lead experts from USPSTF. STUDY SELECTION: We identified 18 articles that met our inclusion/exclusion criteria. Three studies in two publications addressed key question 2 (Does risk factor assessment accurately identify infants who may benefit from bilirubin testing?), nine studies addressed key question 3 (Does bilirubin testing accurately identify infants who may benefit from phototherapy?), and nine studies addressed key question 6 (What are the harms of treatment with phototherapy?). Of the 11 studies that addressed key questions 2 and 3, five were of fair quality; six were of poor quality according to US Preventive Services Task Force (USPSTF) criteria. We did not grade the methodological quality for the nine studies that addressed key question 6. DATA EXTRACTION: Data elements were abstracted on to standardized forms and included information about the study setting, population, control, description of screening strategy, definitions of bilirubin encephalopathy and elevated bilirubin, and methods of analyses. Any adverse events or other effects from screening or phototherapy were also extracted. We also assessed the internal validity of the studies according to USPSTF criteria. DATA SYNTHESIS (RESULTS): There was no study that directly addressed the effectiveness of using risk factor assessment and/or bilirubin testing to reduce the incidence of kernicterus. Three fair quality studies (two nested case-control studies and a large retrospective cohort) examined the effectiveness of either using a risk score or a risk index to predict significant hyperbilirubinemia. The data suggest comparable predictability of the risk score (newborn and familial jaundice history and clinical characteristics) and the modified risk index (i.e., the risk score without family history of jaundice in a newborn) in predicting later significant hyperbilirubinemia. Three fair quality studies (one prospective and two retrospective cohorts) and one poor quality prospective study suggest comparable diagnostic abilities of early total serum bilirubin (TSB) measurements to predict late high TSB measurements. Results from one fair quality retrospective study comparing the ability of various screening strategies in predicting later hyperbilirubinemia suggest that the combination of using the modified risk index with early TSB levels significantly enhanced prediction than using either one of the strategies alone. None of the studies in this review assessed potential harms of screening. Studies in this review did not evaluate the effectiveness of phototherapy in reducing the risk of bilirubin encephalopathy. Our previous review reported that one needs to treat six to ten otherwise healthy jaundiced neonates with TSB Æ15 mg/dL by phototherapy in order to prevent the TSB in one infant from rising above 20 mg/dL. No definitive harm could be attributed to phototherapy. One retrospective study found an association in children between sizes of melanocytic nevi and exposure to neonatal phototherapy. CONCLUSIONS: A study that directly evaluates the effectiveness of different strategies to reduce the incidence of kernicterus is not feasible given the rare occurrence of kernicterus. For practical consideration, studies on the effectiveness of different strategies to reduce the incidence of bilirubin encephalopathy could only rely on a surrogate outcome like serum bilirubin level. Based on retrospective analyses among infants who had both early and late TSB measurements available, the combination of risk factors and early TSB measurement has better diagnostic ability to predict clinically significant hyperbilirubinemia compared to risk factors alone
Member of
Cataloging source
DNLM
Funding information
This report is based on research conducted by the Tufts-New England Medical Center Evidence-based Practice Center (EPC) Tufts-New England Medical Center, 800 Washington Street, Box 63, Boston, Massachusetts 02111. under contract to the Agency for Healthcare Research and Quality (AHRQ) 540 Gaither Road, Rockville, MD 20850. www.ahrq.gov (Contract No. 290-02-0022).
Government publication
federal national government publication
Illustrations
illustrations
Index
no index present
Literary form
non fiction
Nature of contents
  • dictionaries
  • bibliography
NLM call number
WL 362
http://library.link/vocab/relatedWorkOrContributorName
  • Ip, Stanley
  • Tufts-New England Medical Center
  • United States
Series statement
  • Evidence syntheses
  • AHRQ publication
Series volume
no. 10-05140-EF-1
http://library.link/vocab/subjectName
  • Kernicterus
  • Neonatal Screening
  • Bilirubin
  • Risk Assessment
  • Predictive Value of Tests
  • Review
Label
Screening for bilirubin encephalopathy, investigators, Stanley Ip ... [et al.], (electronic resource)
Instantiates
Publication
Note
Title from Bookshelf document home page
Bibliography note
Includes bibliographical references
Dimensions
unknown
Extent
1 online resource.
Form of item
online
Specific material designation
remote
System control number
  • 1553632
  • (DNLM)BKSHLF:NBK34036
Label
Screening for bilirubin encephalopathy, investigators, Stanley Ip ... [et al.], (electronic resource)
Publication
Note
Title from Bookshelf document home page
Bibliography note
Includes bibliographical references
Dimensions
unknown
Extent
1 online resource.
Form of item
online
Specific material designation
remote
System control number
  • 1553632
  • (DNLM)BKSHLF:NBK34036

Library Locations

  • African Studies LibraryBorrow it
    771 Commonwealth Avenue, 6th Floor, Boston, MA, 02215, US
    42.350723 -71.108227
  • Alumni Medical LibraryBorrow it
    72 East Concord Street, Boston, MA, 02118, US
    42.336388 -71.072393
  • Astronomy LibraryBorrow it
    725 Commonwealth Avenue, 6th Floor, Boston, MA, 02445, US
    42.350259 -71.105717
  • Fineman and Pappas Law LibrariesBorrow it
    765 Commonwealth Avenue, Boston, MA, 02215, US
    42.350979 -71.107023
  • Frederick S. Pardee Management LibraryBorrow it
    595 Commonwealth Avenue, Boston, MA, 02215, US
    42.349626 -71.099547
  • Howard Gotlieb Archival Research CenterBorrow it
    771 Commonwealth Avenue, 5th Floor, Boston, MA, 02215, US
    42.350723 -71.108227
  • Mugar Memorial LibraryBorrow it
    771 Commonwealth Avenue, Boston, MA, 02215, US
    42.350723 -71.108227
  • Music LibraryBorrow it
    771 Commonwealth Avenue, 2nd Floor, Boston, MA, 02215, US
    42.350723 -71.108227
  • Pikering Educational Resources LibraryBorrow it
    2 Silber Way, Boston, MA, 02215, US
    42.349804 -71.101425
  • School of Theology LibraryBorrow it
    745 Commonwealth Avenue, 2nd Floor, Boston, MA, 02215, US
    42.350494 -71.107235
  • Science & Engineering LibraryBorrow it
    38 Cummington Mall, Boston, MA, 02215, US
    42.348472 -71.102257
  • Stone Science LibraryBorrow it
    675 Commonwealth Avenue, Boston, MA, 02445, US
    42.350103 -71.103784
Processing Feedback ...